Single-ingredient riboflavin,
does it really help with Reduction of persistent fatigue in quiescent inflammatory bowel disease?
research showsThe documented search did not identify a directly eligible result testing B2 alone for persistent fatigue in quiescent IBD. The current judgment is ? with no numerical score. Associations between B2-related blood markers and fatigue may motivate research, but are not recast as evidence that giving B2 improves fatigue.
ads claimAdvertising and mechanistic claims were not used as grade bonuses or direct clinical evidence.
Four separate assessment dimensions
| Effect direction and size | The documented search did not identify a directly eligible result testing B2 alone for persistent fatigue in quiescent IBD. The current judgment is ? with no numerical score. Associations between B2-related blood markers and fatigue may motivate research, but are not recast as evidence that giving B2 improves fatigue. |
|---|---|
| Evidence certainty | The rubric’s no-identified-directly-eligible-human-result rule gives ? and null. This does not mean null trials have accumulated, so it is not converted to D or F. It follows from not relabeling a B1 intervention as B2 or an observational vitamer association as a B2 treatment effect. |
| Applicability | Adults with persistent fatigue in quiescent IBD; distinct from general energy, acute exercise recovery and confirmed B2-deficiency correction |
| Safety | Dose, duration and adverse-event denominators for this exact B2-alone IBD-fatigue question were not verified. Safety from a B1 trial or the general nutritional necessity of a vitamin is not converted into safety or efficacy of high-dose B2 treatment. |
Not official GRADE or treatment-success probability; ? has no score.
Useful facts when choosing a product
- This is a question about ordinary oral B2 alone. Exact salt, formulation, deficiency status, actual comparator and effect estimates are unconfirmed. Circulating vitamers such as FMN are kept separate from the molecular form of an administered product.
Chamgap Semantic Classification Code
Permanent code issued
S.riboflavin.oral.quiescent-ibd-persistent-fatigue.reduce.placebo-or-no-additionSupplements > Single-ingredient riboflavin > Oral > Persistent fatigue in quiescent inflammatory bowel disease > Reduction claim > Placebo or no addition
Technically bound to the current-value claim boundary fixed by ChatGPT. Unconfirmed dose, duration, study details, and evidence grade remain in verdict fields and revision history rather than the permanent semantic code. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Single-ingredient riboflavin (vitamin B2) |
| Source or part used | Synthetic/fermentation/other production origin unconfirmed; plant-part classification not applicable |
| Formulation or processing | Question: ordinary riboflavin alone by mouth; excludes B1 therapy, B-vitamin combinations and circulating-vitamer analyses |
| Route | Oral (page question; see observed_evidence for study-route verification) |
| Dose | Dose in an eligible B2-alone study unconfirmed |
| Duration | Duration in an eligible B2-alone study unconfirmed |
| Population | Adults with persistent fatigue in quiescent IBD; distinct from general energy, acute exercise recovery and confirmed B2-deficiency correction |
| Effect or condition | Reduction of persistent fatigue in quiescent inflammatory bowel disease |
| Primary endpoint | Change in a validated persistent-fatigue scale; actual B2 trial scale unconfirmed |
| Comparator | Question: placebo/no addition on matched usual IBD care; eligible comparative results unconfirmed |
| Duplicate-detection key | riboflavin-single|oral|dose-unconfirmed|duration-unconfirmed|quiescent-ibd-persistent-fatigue|validated-fatigue-scale-unconfirmed|placebo-or-no-addition-question |
What the research actually shows
The TARIF vitamer paper actually administered B1, as thiamine hydrochloride. Another IBD combination trial used B1, B6, B12 and magnesium rather than B2. The riboflavin (B2) ultramarathon study addressed acute soreness and performance recovery, not persistent IBD fatigue.
Why this is classified as ?
The rubric’s no-identified-directly-eligible-human-result rule gives ? and null. This does not mean null trials have accumulated, so it is not converted to D or F. It follows from not relabeling a B1 intervention as B2 or an observational vitamer association as a B2 treatment effect.
Counterpoint. This is related to the general energy–fatigue claim in existing verdict 374, but the present page fixes quiescent IBD, persistent fatigue and B2 alone. The existing score or combination findings in 374 are neither recalculated nor copied.
Rejudgment record. The documented search did not identify a directly eligible result testing B2 alone for persistent fatigue in quiescent IBD. The current judgment is ? with no numerical score. Associations between B2-related blood markers and fatigue may motivate research, but are not recast as evidence that giving B2 improves fatigue. — The rubric’s no-identified-directly-eligible-human-result rule gives ? and null. This does not mean null trials have accumulated, so it is not converted to D or F. It follows from not relabeling a B1 intervention as B2 or an observational vitamer association as a B2 treatment effect.
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests Case application: Defines the question, not an observed eligible trial; unused scoring axes remain null |
Stored derived and displayed grades match; this is not a current recalculation or validity check (?).
Review performed and remaining limitations
B2-alone fatigue effect and treatment details in quiescent IBD unconfirmed Native databases worldwide were not exhaustively searched; the current judgment is published with that limitation.
Search scope and limitations. tasks/R01-008/search_log.json
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| B-vitamins and metabolites in quiescent IBD with fatigue treated with oral thiamine (2023) | Excluded: observational analysis of a different intervention | Only verified denominators are recorded in numeric_evidence.json; assignment totals are not substituted for unknown endpoint analysis counts. | Unconfirmed or not used in this page grade | B-vitamer and fatigue analyses in participants in a B1 trial; not a B2 supplementation contrast | The trial intervention was oral thiamine hydrochloride. B2-related vitamer analyses belong to the same TARIF family and are not a B2 supplementation trial. | Excluded: observational analysis of a different intervention |
| Vitamin B complex plus magnesium and fatigue in IBD (2026) | Excluded: different or confounded intervention | Only verified denominators are recorded in numeric_evidence.json; assignment totals are not substituted for unknown endpoint analysis counts. | Unconfirmed or not used in this page grade | IBD fatigue with a B-vitamin–magnesium combination, not isolated B1/B2 | The combination intervention contains B1, B6, B12 and magnesium. Its results are not assigned to B2 or to isolated B1. | Excluded: different or confounded intervention |
| Hoffman et al. — riboflavin and ultramarathon recovery (2017) | Excluded: different population or endpoint | Only verified denominators are recorded in numeric_evidence.json; assignment totals are not substituted for unknown endpoint analysis counts. | Unconfirmed or not used in this page grade | Acute soreness and recovery performance after an ultramarathon, not chronic IBD fatigue | The ultramarathon recovery trial assessed acute soreness and recovery performance, a different population and endpoint from persistent fatigue in quiescent IBD. | Excluded: different population or endpoint |
Receipt — 3 References
Evidence access cutoff: 2026-09-15. Each citation states its actual access level (full-text transcription, abstract, index, or other) and remaining limitations. Bibliographic checking does not certify the study results or treatment efficacy.
Technical integration by: Codex · Evidence date: 2026-09-15 · Corrections: 1
Correction log — 1
Corrections applied to this verdict, in chronological order. Changes are logged, not erased.
- 2026-09-15 · current_value_initial_publication — B1 trials and vitamer associations were not counted as B2 clinical trials; a combination without B2 was excluded from B2 evidence.
Cite this verdict
[Chamgap] Single-ingredient riboflavin (vitamin B2) × Reduction of persistent fatigue in quiescent inflammatory bowel disease — Evidence Grade ?. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/energy/oral-riboflavin-quiescent-ibd-fatigue/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.